In Re Pacific Fertility Center Litigation

District Court, N.D. California·Decided March 5, 2021·No. 3:18-cv-01586·Unknown

Opinion

1 2 3 4 5 6 7 UNITED STATES DISTRICT COURT 8 NORTHERN DISTRICT OF CALIFORNIA 9 10 IN RE PACIFIC FERTILITY CENTER Case No. 18-cv-01586-JSC

11 LITIGATION ORDER RE: CHART’S MOTIONS TO 12 EXCLUDE PLAINTIFFS’ EXPERTS 13 Dkt. Nos. 629, 631 14

15 16 Plaintiffs bring product liability and failure to recall claims against Chart Industries 17 following a March 2018 incident involving a Chart-manufactured cryopreservation tank which 18 was storing Plaintiffs’ eggs and embryos. In connection with summary judgment and in 19 preparation for trial, the parties have each filed motions to exclude the other’s expert testimony in 20 whole or in part under the Federal Rules of Evidence and Daubert v. Merrell Dow Pharm., Inc., 21 509 U.S. 579 (1993).1 (Dkt. Nos. 629, 631, 632. 2) This Order focuses on Chart’s motions to 22 exclude Plaintiffs’ experts Dr. Kasbekar, Dr. Wininger, and Dr. Grill. Having considered the 23 parties’ briefing regarding these motions and having had the benefit of oral argument on March 4, 24 2021, Chart’s motions are DENIED for the reasons set forth below. 25 // 26 1 All parties have consented to the jurisdiction of a magistrate judge pursuant to 28 U.S.C. § 27 636(c). (Dkt. No. 553.) 1 BACKGROUND 2 Plaintiffs obtained fertility services from Pacific Fertility Center (PFC)3, and in particular, 3 as relevant here, cryopreservation of their eggs and embryos. On March 4, 2018, PFC’s laboratory 4 director, Dr. Joseph Conaghan, discovered that Tank 4 which contained 2,500 embryos and 1,500 5 eggs—including Plaintiffs’ eggs and embryos—had lost liquid nitrogen. As a result of this 6 incident, Plaintiffs filed the underlying action against Chart alleging manufacturing and design 7 defects, as well as negligent failure to recall.4 Chart denies any liability and insists that the Tank 4 8 incident occurred because of PFC’s negligence. 9 Over 130 individual actions alleging these same claims against Chart have been 10 consolidated with the Plaintiffs’ claims here. The claims of the five original Plaintiffs, A.B., C.D., 11 E.F., G.H., and I.J. are scheduled for trial May 3, 2021. 12 LEGAL STANDARD 13 Under Rule 702 of the Federal Rules of Evidence, a witness may offer expert testimony if 14 the following requirements are met:

15 (a) the expert’s scientific, technical, or other specialized knowledge will help the trier of fact to understand the 16 evidence or to determine a fact in issue;

17 (b) the testimony is based on sufficient facts or data;

18 (c) the testimony is the product of reliable principles and methods; and 19 (d) the expert has reliably applied the principles and methods 20 to the facts of the case. 21 Fed. R. Evid. 702. These criteria can be distilled to two overarching considerations: “reliability 22 and relevance.” Ellis v. Costco Wholesale Corp., 657 F.3d 970, 982 (9th Cir. 2011). The inquiry 23 does not, however, “require a court to admit or exclude evidence based on its persuasiveness.” Id. 24 Scientific evidence is reliable “if the principles and methodology used by an expert are 25

26 3 The Court uses PFC throughout this Order to refer to Pacific Fertility Center and all its associated entities and medical professionals, including Prelude Fertility, Inc., and Pacific MSO, 27 LLC. 1 grounded in the methods of science.” Clausen v. M/V New Carissa, 339 F.3d 1049, 1056 (9th Cir. 2 2003). The court’s focus “must be solely on principles and methodology, not on the conclusions 3 that they generate.” See Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579, 595 (1993). The 4 court’s “task ... is to analyze not what the experts say, but what basis they have for saying it.” 5 Daubert v. Merrell Dow Pharmaceuticals, Inc., 43 F.3d 1311, 1316 (9th Cir. 1995) (hereinafter 6 Daubert II). 7 In deciding whether to permit an expert to testify, courts face the difficult task of 8 “determin[ing] whether the analysis undergirding the experts’ testimony falls within the range of 9 accepted standards governing how scientists conduct their research and reach their conclusions.” 10 Daubert II, 43 F.3d at 1317. Among the factors courts consider in making this determination are: 11 (1) whether the expert’s theory or method is generally accepted in the scientific community; (2) 12 whether the expert’s methodology can be or has been tested; (3) the known or potential error rate 13 of the technique; and (4) whether the method has been subjected to peer review and publication. 14 Id. at 1316 (citing Daubert, 509 U.S. at 593-94). Consideration should also be given to whether 15 the expert’s testimony springs from research independent of the litigation. Id. at 1317. If not, the 16 expert should point to other indicia of reliability, such as peer-reviewed studies or a reputable 17 source showing that the expert “followed the scientific method, as it is practiced by (at least) a 18 recognized minority of scientists in their field.” Id. at 1317-19. “These factors are illustrative, and 19 they are not all applicable in each case.” Wendell v. GlaxoSmithKline LLC, 858 F.3d 1227, 1233 20 (9th Cir. 2017). The inquiry is “flexible,” Daubert, 509 U.S. at 594, and “Rule 702 should be 21 applied with a ‘liberal thrust’ favoring admission,” Messick, 747 F.3d at 1196 (quoting Daubert, 22 509 U.S. at 588). 23 DISCUSSION 24 Chart moves to exclude the opinions of three of Plaintiffs’ experts: Dr. Kasbekar, Dr. 25 Wininger, and Dr. Grill under Federal Rule of Evidence 702 and Daubert. (Dkt. Nos. 629, 631.) 26 A. Dr. Anand David Kasbekar 27 Dr. Kasbekar is a mechanical engineer with over 35 years’ experience working as a 1 reconstruction, computer aided engineering, modeling, simulation, and visualization. (Dkt. No. 2 673-9 at 64.) Plaintiffs retained Dr. Kasbekar to evaluate the current condition of Tank 4 and 3 investigate the cause of Tank 4’s failure. 4 Chart moves to exclude Dr. Kasbekar’s testimony because (1) he is not qualified; (2) he 5 used flawed methodology; and (3) his rebuttal Finite Element Analyses (FEA) is untimely and 6 relies on flawed methodology. 7 1) Dr. Kasbekar is Qualified to Render a Causation Opinion 8 With respect to his qualifications, Chart argues that Dr. Kasbekar lacks the expertise to 9 testify regarding cryogenic storage devices because he is a “jack-of-all-trades mechanical 10 engineer” and not a cryogenic engineer. (Dkt. No. 692 at 11.) Plaintiffs insist that 11 notwithstanding his lack of cryogenic specialization he is qualified to render a causation opinion 12 here because of his experience analyzing failed metal and plastic components and his routine 13 examination of “fractured components.” (Dkt. No. 673-6 at 9.) The Court agrees. 14 Rule 702 states that a testifying expert be “qualified as an expert by knowledge, skill, 15 experience, training, or education.” Fed. R. Evid.

Free access — add to your briefcase to read the full text and ask questions with AI

In Re Pacific Fertility Center Litigation, (N.D. Cal. 2021).

In Re Pacific Fertility Center Litigation (In Re Pacific Fertility Center Litigation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Primiano v. Cook
598 F.3d 558 (Ninth Circuit, 2010)
Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
Ellis v. Costco Wholesale Corp.
657 F.3d 970 (Ninth Circuit, 2011)
United States v. Richard Joseph Finley
301 F.3d 1000 (Ninth Circuit, 2002)
Schipp Ex Rel. Estate of Neufelder v. General Motors Corp.
443 F. Supp. 2d 1023 (E.D. Arkansas, 2006)
City of Pomona v. Sqm North America Corporation
750 F.3d 1036 (Ninth Circuit, 2014)
Stephen Wendell v. Glaxosmithkline LLC
858 F.3d 1227 (Ninth Circuit, 2017)
Demara v. Raymond Corp.
221 Cal. Rptr. 3d 102 (California Court of Appeals, 5th District, 2017)
Daubert v. Merrell Dow Pharmaceuticals, Inc.
43 F.3d 1311 (Ninth Circuit, 1995)
In re Roundup Prods. Liab. Litig.
390 F. Supp. 3d 1102 (N.D. California, 2018)
Clausen v. M/V New Carissa
339 F.3d 1049 (Ninth Circuit, 2003)